Delivery Order SPE2DB20D2001-SPE2DB23FM69U
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, is a $2,248.40 firm fixed price delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of Lyrica 300 mg capsules, a prescription medication, to support military treatment programs and facilities. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at...
- This federal contract award, valued at $2,641.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is a delivery order for the supply of Lyrica 100 mg capsules, with a completion date of April 25, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025. This IDC serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a major defense agency, to Amerisourcebergen Drug Corp's Corporate Office Division. The contract, valued up to $1,146.00, is for the delivery of Lyrica 150 mg capsules. This is a firm fixed price, delivery order contract with an ultimate completion date of October 1, 2024. The contract does not have a set-aside designation. Amerisourcebergen, a large pharmaceutical distributor, has been awarded...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was issued by the Defense Logistics Agency (DLA) Troop Support Medical as a firm fixed price delivery order for the supply of 100 mg Lyrica capsules. The contract has a potential value of $2,397.92 and a performance period through February 29, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00...
- This federal contract award is for the delivery of Lyrica 50 mg capsules to support the Defense Logistics Agency (DLA) Troop Support Medical. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed-price pricing type, valued at $1,616.22. It has an ultimate completion date of March 27, 2024. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,828.82 firm-fixed-price delivery order is for the supply of Lyrica 150 mg capsules. Amerisourcebergen holds a large Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 with DLA Troop Support Medical through December 2025, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and...
- The Defense Logistics Agency (DLA) awarded a $4,707.60 firm fixed price delivery order for Lyrica 75 mg capsules to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. This order is part of Amerisourcebergen Drug Corp's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. Amerisourcebergen Drug Corp provides a comprehensive range of pharmaceutical products and medical supplies to...
- This federal contract award is for the delivery of Lyrica 150 mg capsules to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm fixed-price delivery order with a ceiling value of $12,585.75 and a completion date of May 13, 2022. There is no set-aside designation for this award. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract has a ceiling value of $6,464.88 and is for the delivery of Lyrica 50 mg capsules. The contract is a firm fixed price agreement with a performance period running through March 15, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued at up to $999,999,999.00 through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the delivery of Lyrica 150 mg capsules. The contract has a ceiling value of $1,613.70 and is a firm fixed-price delivery order that does not have a set-aside designation. The contract has an ultimate completion date of September 13, 2024. AmerisourceBergen, as a major pharmaceutical distributor, has been awarded multiple indefinite delivery contracts (IDCs) by the DLA and...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB23FM69UDelivery Order
This federal contract award is for the delivery of Lyrica 150 mg capsules to support the Defense Logistics Agency (DLA) Troop Support Medical program. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $3,347.23 and an ultimate completion date of August 23, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract award is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also maintains a smaller IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/22/23 |